🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
1.810
-0.050 (-2.69%)
At close: Nov 20, 2026, 4:00 PM EST
1.840
+0.030 (1.66%)
After-hours: Nov 20, 2026, 5:33 PM EST

BBOT Stock Forecast

BBOT's stock price has decreased by -85.73% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 12 analysts polled by S&P Global, BBOT stock has a consensus rating of "Strong Buy" and an average price target of $20.91. The average 1-year stock price forecast is 1,055.25% higher than the current stock price, while the lowest is $9.00 (+397.24%) and the highest is $50 (+2,662.43%).

Price Target: $20.91 (+1,055.25%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$9.00$20.91$17$50
Change+397.24%+1055.2%+839.23%+2662.4%

Analyst Ratings

The average analyst rating for BBOT stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy777888
Buy344444
Hold000000
Sell000000
Strong Sell000000
Total101111121212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$13 → $12
BuyReiterates$13 → $12+562.98%Nov 18, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$17
BuyMaintains$17+839.23%Nov 16, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$20
BuyMaintains$20+1,004.97%Nov 12, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$16
BuyMaintains$16+783.98%Nov 12, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Maintains
$15
BuyMaintains$15+728.73%Nov 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.20
from -4.30
EPS Next Year
-2.09
from -2.20
Fiscal YearFY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
----
Operating Income
-64.77M-80.86M-145.82M-183.59M
Net Income
-64.70M-74.28M-134.04M-170.33M
EPS
---4.30-2.20
Free Cash Flow
----17.00M
No. Analysts
---9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.62
Avg-2.20
Low-3.69

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-